2020
DOI: 10.1186/s12967-020-02219-w
|View full text |Cite
|
Sign up to set email alerts
|

Is there a causal link between PTEN deficient tumors and immunosuppressive tumor microenvironment?

Abstract: The PTEN tumor suppressor is the second most commonly inactivated gene across cancer types. While it's role in PI3K/AKT and DNA damage pathways are clear, increasing evidences suggest that PTEN may also promote anti-tumor immunity. PTEN-deficient tumors are characterized by (i) reduced levels of cytotoxic T cells, helper T cells and NK cells, (ii) elevated pro-oncogenic inflammatory cytokines like CCL2 and (iii) increased levels of immunosuppressive cells such as MDSCs and Tregs. An intriguing possibility is t… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
47
0
1

Year Published

2020
2020
2024
2024

Publication Types

Select...
7
3

Relationship

0
10

Authors

Journals

citations
Cited by 54 publications
(48 citation statements)
references
References 97 publications
(146 reference statements)
0
47
0
1
Order By: Relevance
“…In particular, PTEN expression (or lack thereof) in cancer cells attracts different immune cell populations to the TME; on the other hand, PTEN function in immune cells regulates their activation status [8]. As schematically depicted in Figure 1, the overall effect of PTEN loss of function in different cellular compartments shifts the balance towards an immunosuppressive TME [47][48][49]. Here, we give a comprehensive overview of the potential role of PTEN in the regulation of the immunosuppressive aspects of the TME (Figure 1).…”
Section: Pten In Immunoevasionmentioning
confidence: 99%
“…In particular, PTEN expression (or lack thereof) in cancer cells attracts different immune cell populations to the TME; on the other hand, PTEN function in immune cells regulates their activation status [8]. As schematically depicted in Figure 1, the overall effect of PTEN loss of function in different cellular compartments shifts the balance towards an immunosuppressive TME [47][48][49]. Here, we give a comprehensive overview of the potential role of PTEN in the regulation of the immunosuppressive aspects of the TME (Figure 1).…”
Section: Pten In Immunoevasionmentioning
confidence: 99%
“…Furthermore, V158F has been predicted to lead to PTEN inactivation. In patients with HER-2-positive GC, PTEN deletion mutations are associated with Trastuzumab resistance, and the loss of heterozygosis of this gene has been reported more frequently in GC [42]. The relationship between PTEN protein deletion and various gene alterations in GC is not clear.…”
Section: Discussionmentioning
confidence: 99%
“…It is predicted that V158fs will lead to the inactivation of PTEN. In HER-2 positive GC patients, PTEN deletion mutations are associated with Trastuzumab resistance, and the loss of heterozygosis of this gene has been reported more frequently in gastric cancer [31]. In solid tumor patients receiving immunotherapy, the median OS of patients with POLE/POLD1 mutation was signi cantly better than that of non-carriers.…”
Section: Discussionmentioning
confidence: 99%